

June 3, 2016

---

# Can-Fite to Exhibit at Bio International Convention in San Francisco on June 6-9, 2016

## Company also to participate as a member of the Israeli Biotech Delegation at Perspectives on Biotech Investing on June 6

PETACH TIKVA, Israel, June 3, 2016 /PRNewswire/ -- [Can-Fite BioPharma Ltd.](#) (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the Company will exhibit at the Bio International Convention on June 6-9, 2016, in San Francisco at the Israel Office of the Chief Scientist's booth. Dr. Sari Fishman, the Company's Director of Business Development, will conduct one-on-one meetings with potential big pharma and biotech partners at the convention. In addition, Dr. Fishman will be part of an Israeli Biotech Delegation participating in a satellite event titled, [Perspectives on Biotech Investing](#) on June 6, where Can-Fite will participate in a pitch session for attendees interested in Israel's biotech economy and companies.

The BIO International Convention ([BIO](#)) attracts over 15,000 biotechnology and pharma leaders who come together for intensive networking to discover new opportunities and promising partnerships. This event covers a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

### **About Can-Fite BioPharma Ltd.**

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2016 for two indications, rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug CF102 is in Phase II trials for patients with liver cancer and is slated to enter Phase II for the treatment of non-alcoholic steatohepatitis (NASH). CF102 has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared for an IND submission to the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information please visit: [www.can-fite.com](http://www.can-fite.com).

### **Forward-Looking Statements**

This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

#### Contact

Can-Fite BioPharma  
Motti Farbstein  
[info@canfite.com](mailto:info@canfite.com)  
+972-3-9241114

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/can-fite-to-exhibit-at-bio-international-convention-in-san-francisco-on-june-6-9-2016-300279511.html>

SOURCE Can-Fite BioPharma Ltd.